An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...

An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...

This article presents the currently available mucosal vaccines and their principle mechanisms of action. The concepts of live attenuated and non-living subcomponent vaccines are explained ...